Gird your kidneys? A novel approach to ADPKD therapeutics

Mallett, Andrew

Abstract

[Extract] The need remains high to identify new and novel treatments for autosomal dominant polycystic kidney disease (ADPKD), especially those that might slow the rate of decline of kidney function given that it is the most common heritable form of chronic kidney disease [1]. The first directed therapy for ADPKD has generated substantial impact as the evidence for its efficacy and role has accumulated [2]. Tolvaptan has however been associated with some challenges to implementation due to symptoms, side effects, and variability in licensing and/or funding across different jurisdictions globally. Consequently, substantial activity continues in order to identify additional therapeutic approaches to ameliorate or slow ADPKD pathobiology and clinical sequelae [3]. To date, the vast majority, if not all of these approaches that have been investigated in preclinical models or clinical trials have been pharmacological interventions.

Journal

Journal of Nephrology

Publication Name

N/A

Volume

ISBN/ISSN

1724-6059

Edition

N/A

Issue

N/A

Pages Count

Location

N/A

Publisher

Springer

Publisher Url

N/A

Publisher Location

N/A

Publish Date

N/A

Url

N/A

Date

N/A

EISSN

N/A

DOI

10.1007/s40620-022-01425-7